Seventy patients benefited from molecular analysis with the local high throughput sequencing AML minimal panel searching for mutations of NPM1, FLT3ITD, IDH1, IDH2, ASXL1, RUNX1, TP53 at diagnosis. This evidence concerns the gene IDH2 and acute myeloid leukemia.